Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F15%3A10311892" target="_blank" >RIV/00216208:11140/15:10311892 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00669806:_____/15:10311892 RIV/00023001:_____/15:00059425

Výsledek na webu

<a href="http://dx.doi.org/10.3748/wjg.v21.i18.5496" target="_blank" >http://dx.doi.org/10.3748/wjg.v21.i18.5496</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3748/wjg.v21.i18.5496" target="_blank" >10.3748/wjg.v21.i18.5496</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection

Popis výsledku v původním jazyce

AIM: To identify predictors of sustained virological response in hemodialysed patients treated by PEGinterferon alpha for chronic hepatitis C, genotype 1. METHODS: The sustained virological response (SVR) rate, IL28B genotype, IFNL4 genotype, initial viral load (IVL) and other pretreatment variables in 39 end-stage renal disease patients (ESRD) on maintenance haemodialysis (HD) infected with hepatitis C virus (HCV), genotype 1b, were compared with a control group of 109 patients with normal kidney function treated within the same period. All the patients were treatment naive and had well compensated liver disease. The ESRD patients received 135 mu g of PEGylated interferon alpha-2a (PegIFN-alpha) weekly and a reduced dose of ribavirin (RBV) was administered to 23/39 patients with an initial haemoglobin level > 10 g/dL. Control group patients were given standard doses of PegIFN-alpha and RBV. SVR was assessed as hcv RNA negativity 24 wk post-treatment. A t-test or ANOVA were used for co

Název v anglickém jazyce

Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection

Popis výsledku anglicky

AIM: To identify predictors of sustained virological response in hemodialysed patients treated by PEGinterferon alpha for chronic hepatitis C, genotype 1. METHODS: The sustained virological response (SVR) rate, IL28B genotype, IFNL4 genotype, initial viral load (IVL) and other pretreatment variables in 39 end-stage renal disease patients (ESRD) on maintenance haemodialysis (HD) infected with hepatitis C virus (HCV), genotype 1b, were compared with a control group of 109 patients with normal kidney function treated within the same period. All the patients were treatment naive and had well compensated liver disease. The ESRD patients received 135 mu g of PEGylated interferon alpha-2a (PegIFN-alpha) weekly and a reduced dose of ribavirin (RBV) was administered to 23/39 patients with an initial haemoglobin level > 10 g/dL. Control group patients were given standard doses of PegIFN-alpha and RBV. SVR was assessed as hcv RNA negativity 24 wk post-treatment. A t-test or ANOVA were used for co

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

<a href="/cs/project/NT11235" target="_blank" >NT11235: Úloha faktorů hostitele v odpovědi na protivirovou léčbu chronické hepatitidy C</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

World Journal of Gastroenterology

ISSN

1007-9327

e-ISSN

—

Svazek periodika

21

Číslo periodika v rámci svazku

18

Stát vydavatele periodika

CN - Čínská lidová republika

Počet stran výsledku

9

Strana od-do

5496-5504

Kód UT WoS článku

000354800200007

EID výsledku v databázi Scopus

2-s2.0-84929166244